Santen Pharmaceutical Co Stock

Santen Pharmaceutical Co Liabilities 2024

Santen Pharmaceutical Co Liabilities

129.65 B JPY

Ticker

4536.T

ISIN

JP3336000009

WKN

864318

In 2024, Santen Pharmaceutical Co's total liabilities amounted to 129.65 B JPY, a 5.84% difference from the 122.49 B JPY total liabilities in the previous year.

Santen Pharmaceutical Co Aktienanalyse

What does Santen Pharmaceutical Co do?

Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the development and marketing of pharmaceutical products and medical devices. With its headquarters in Osaka, Japan, Santen was founded in October 1890 as Fukuhara Helper's Institute Co., Ltd. Santen started as a small contact lens manufacturer and distributor in 1936, focusing on producing and selling high-quality contact lenses. Over time, the company expanded its product offerings to include ophthalmic products such as eye drops and other medications. In the 1990s, Santen further expanded its business by acquiring other companies and establishing its own research and development department to develop innovative products. Today, Santen is part of a global network of companies specializing in the development and marketing of ophthalmic products. Santen operates in various business areas, including ophthalmology, dermatological and anti-rheumatic medications, as well as medical devices and diagnostic instruments. The company has a presence in over 60 countries worldwide, with branches in the USA, Europe, and Asia. In the field of ophthalmology, Santen offers a wide range of products for the treatment of eye diseases such as glaucoma, dry eye, and allergic conditions. The company has also developed advanced devices for ophthalmology, such as lasers for the treatment of various eye diseases. Santen has also invested in dermatological medicine by offering medications for various skin conditions, including acne, psoriasis, and eczema. Additionally, the company provides medical devices for the diagnosis and monitoring of skin conditions. Specializing in the development of anti-rheumatic medications, Santen offers therapies for conditions such as rheumatoid arthritis and psoriatic arthritis. The company has collaborated with other companies to develop innovations in this field. Santen's business model revolves around developing and marketing innovative products for the healthcare industry. The company aims to provide patients worldwide with access to the best treatments and medical devices. Santen prioritizes research and development, investing a significant portion of its revenue in the development of new products. Overall, Santen offers a wide range of products and services that are in high demand in the healthcare sector. The company has established itself as an innovative provider of top-quality solutions in ophthalmology, dermatology, and rheumatology worldwide. With its strong presence in various countries, Santen continues to invest in the research and introduction of new products that can improve the health and well-being of people. Santen Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Santen Pharmaceutical Co's Liabilities

Santen Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Santen Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Santen Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Santen Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Santen Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Santen Pharmaceutical Co stock

What is the level of liabilities of Santen Pharmaceutical Co this year?

Santen Pharmaceutical Co has a debt balance of 129.65 B JPY this year.

What were the liabilities of Santen Pharmaceutical Co compared to the previous year?

The liabilities of Santen Pharmaceutical Co have increased by 5.84% increased compared to the previous year.

What are the consequences of high debt for investors of Santen Pharmaceutical Co?

High liabilities can pose a risk for investors of Santen Pharmaceutical Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Santen Pharmaceutical Co?

Low liabilities mean that Santen Pharmaceutical Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Santen Pharmaceutical Co affect the company?

An increase in liabilities of Santen Pharmaceutical Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Santen Pharmaceutical Co affect the company?

A decrease in the liabilities of Santen Pharmaceutical Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Santen Pharmaceutical Co?

Some factors that can influence the liabilities of Santen Pharmaceutical Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Santen Pharmaceutical Co so important for investors?

The liabilities of Santen Pharmaceutical Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Santen Pharmaceutical Co take to modify the liabilities?

To change its liabilities, Santen Pharmaceutical Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Santen Pharmaceutical Co pay?

Over the past 12 months, Santen Pharmaceutical Co paid a dividend of 34 JPY . This corresponds to a dividend yield of about 1.89 %. For the coming 12 months, Santen Pharmaceutical Co is expected to pay a dividend of 34.87 JPY.

What is the dividend yield of Santen Pharmaceutical Co?

The current dividend yield of Santen Pharmaceutical Co is 1.89 %.

When does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Santen Pharmaceutical Co?

Santen Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Santen Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 34.87 JPY are expected. This corresponds to a dividend yield of 1.93 %.

In which sector is Santen Pharmaceutical Co located?

Santen Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Santen Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Santen Pharmaceutical Co from 12/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Santen Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Santen Pharmaceutical Co in the year 2023?

In the year 2023, Santen Pharmaceutical Co distributed 32 JPY as dividends.

In which currency does Santen Pharmaceutical Co pay out the dividend?

The dividends of Santen Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Santen Pharmaceutical Co

Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.